Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21324704 | 1.00 | NR1H2 (0.51) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL26422959 | 0.88 | NR1H2 (0.54) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL13110521 | 0.87 | NR1H2 (0.49) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL18115911 | 0.87 | NR1H2 (0.49) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL19990950 | 0.87 | NR1H2 (0.49) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL3449225 | 0.87 | NR1H2 (0.49) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL18115862 | 0.85 | NR1H2 (0.50) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL18115864 | 0.85 | NR1H2 (0.50) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL16080285 | 0.85 | NR1H2 (0.50) | NR1H2HPGDPREPUSP2SMN1; SMN2 | |
| SCHEMBL2739529 | 0.84 | NR1H2 (0.57) | NR1H2HPGDPREPUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | NR1H2 169/4885HPGD 84/4885PREP 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.